Spin offs

<p>Logo Nostrum Biodiscovery</p>

Nostrum Biodiscovery is a biotechnological company focused on the computational biology sector and, specifically, in the structure-based drug design area dedicated to early drug discovery and development based on rational design techniques.

Inbiomotion is a Barcelona-based personalized medicine company incorporated in 2011 with the goal of developing biomarkers that predict bone metastasis to improve the cancer patient’s quality of life.

Iproteos is a biotechnology company focused on the research and development of third-generation drugs based on peptidomimetics for human diseases. The company’s strategy is based on peptidomimetics, molecules able to modulate the activity of undruggable targets, such as Protein-Protein Interactions (PPIs).

Innovation projects

IRB Barcelona Spin offs

Innovation projects

The Innovation Department is an accredited TECNIO agent in the category of Developers and Technology Enablers.

The TECNIO seal is awarded by the Government of Catalonia, through ACCIÓ, and identifies key technology providers and facilitators in Catalonia. This seal supports the most qualified agents involved in technology transfer; allows companies to access advanced R&D to develop new products and services; increases the scope of technology projects by finding the most suitable technology partners & suppliers; and helps raise competitiveness and technological innovation capacities.

VALUNI 2016 aims to promote the commercialization of projects and technologies by supporting key activities that facilitate the licensing of patents and/or creation of technology-based companies. Two projects promoted by the Innovation Department were awarded in 2017: “Colostage Technology” and “Gate2Brain – transport de molècules al cervell”.

Gínjol is a new patent fund set up by CERCA, an organization belonging to the Government of Catalonia that supervises, supports and facilitates the activities of research centres in Catalonia. IRB Barcelona received funding for the two projects submitted by Innovation Department in the first call for application launched at the end of 2016. Two patents at IRB Barcelona were awarded in the first Gínjol call: “Oncoselective mechanism for gene or viral therapy”, and “A novel and promising new target against Alzheimer’s disease".

Noticias

<p>Image of breast cancer cells derived from a mouse mammary tumour (in blue: nucleus, in green: tubulin) Author: Begoña Cánovas, IRB Barcelona</p>
24 May 2018

Conocer al detalle los mecanismos que contribuyen a la supervivencia de las células tumorales ayuda a desarmarlos.

<p>Normal Drosophila melanogaster spermatozoa. Orange shows heads and green shows tails. Photo courtesy of S. Llamazares / Gonzalez Lab</p>
11 May 2018

Un equipo liderado por el investigador ICREA del Instituto de Investigación Biomédica (IRB Barcelona), Cayetano González, en colaboración con el grupo de Giuliano Callaini, de la Universidad de Sie

<p>Mouse cells with DOR protein. (M. Romero, IRB Barcelona)</p>
19 Abr 2018

La obesidad es considerada como un problema de salud mundial porque la acumulación excesiva de tejido graso (o tejido adiposo) incrementa el riesgo de padecer enfermedades cardiovasculares, hiperte

Testimonial

Contacto

Cristina Horcajada
Head of Innovation
Tel: +34 93 40 31193
  • Tecnio Catalonia